114 followers
TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial https://t.co/RClxexO8kr https://t.co/Yx5JtWbT8j